[Skip to Content]
[Skip to Content Landing]
December 13, 1941


Author Affiliations

Department of Pharmacology, Tulane University of Louisiana School of Medicine, New Orleans. Chairman, Subcommittee on Biological Assays, U. S. P. XII Revision Committee.

JAMA. 1941;117(24):2093-2094. doi:10.1001/jama.1941.02820500075026

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  In The Journal, October 11, page 1243, appeared an article calling attention to the increase in potency of the digitalis preparations in the U. S. Pharmacopeia XI, which became official June 1, 1936 (Bland, E. F., and White, Paul D.: The Strength of Digitalis in Clinical Use: A Warning). Unfortunately, not enough publicity was given to the change at the time when it took effect. Further, there has been some controversy as to just what the change was. This communication is written to present the intent of those responsible for the next revision of the U. S. Pharmacopeia.The change in potency made at the time of the last revision was intended to bring the digitalis preparations of the U. S. Pharmacopeia XI into line with those of, countries accepting the League of Nations Standards. In the U. S. Pharmacopeia XI (p. 136) appears the following statement

First Page Preview View Large
First page PDF preview
First page PDF preview